LivaNova (NASDAQ:LIVN) Bolsa

LivaNova

UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

<p>Fortis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTS#NYSE">FTS</a>) is preparing to release its quarterly earnings on Friday, 2025-08-01. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Fortis to report an <strong>earnings per share</strong> (EPS) of $0.51.</p>
<p>Anticipation surrounds Fortis's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.00, leading to a 2.53% drop in the share price the following trading session.</p>
<p>Here's a look at Fortis's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.7</td>
<td>0.57</td>
<td>0.59</td>
<td>0.48</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.7</td>
<td>0.59</td>
<td>0.62</td>
<td>0.49</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.0%</td>
<td>0.0%</td>
<td>-1.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753970558_0.png" alt="eps graph" /></p>
<h3>Market Performance of Fortis's Stock</h3>
<p>Shares of Fortis were trading at $49.0 as of July 30. Over the last 52-week period, shares are up 14.68%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/FTS/earnings"><strong>To track all earnings releases for Fortis visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

Earnings Preview: Fortis

<p><strong>Franklin Resources</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) is set to give its latest quarterly earnings report on Friday, 2025-08-01. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Franklin Resources will report an <strong>earnings per share</strong> (EPS) of $0.48. </p>
<p>Franklin Resources bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.00, leading to a 0.0% drop in the share price the following trading session.</p>
<p>Here's a look at Franklin Resources's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.47</td>
<td>0.53</td>
<td>0.60</td>
<td>0.57</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.47</td>
<td>0.59</td>
<td>0.59</td>
<td>0.60</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>7.000000000000001%</td>
<td>10.0%</td>
<td>4.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753970551_0.png" alt="eps graph" /></p>
<h3>Performance of Franklin Resources Shares</h3>
<p>Shares of Franklin Resources were trading at $24.31 as of July 30. Over the last 52-week period, shares are up 10.76%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Perspectives on Franklin Resources</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Franklin Resources.</p>
<p>With 8 analyst ratings, Franklin Resources has a consensus rating of Neutral. The average one-year price target is $22.25, indicating a potential 8.47% downside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Blue Owl Capital, SEI Investments and Invesco, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Blue Owl Capital, with an average 1-year price target of $22.5, suggesting a potential 7.45% downside.</li>
<li>Analysts currently favor an Outperform trajectory for SEI Investments, with an average 1-year price target of $98.67, suggesting a potential 305.88% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Invesco, with an average 1-year price target of $18.0, suggesting a potential 25.96% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for Blue Owl Capital, SEI Investments and Invesco, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Franklin Resources</td>
<td>Neutral</td>
<td>-1.92%</td>
<td>$1.67B</td>
<td>1.11%</td>
</tr>
<tr>
<td>Blue Owl Capital</td>
<td>Outperform</td>
<td>33.14%</td>
<td>$357.55M</td>
<td>0.33%</td>
</tr>
<tr>
<td>SEI Investments</td>
<td>Outperform</td>
<td>7.83%</td>
<td>$301.13M</td>
<td>9.88%</td>
</tr>
<tr>
<td>Invesco</td>
<td>Neutral</td>
<td>-0.90%</td>
<td>$555.60M</td>
<td>-0.10%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Franklin Resources ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, it is at the bottom.</p>
<h3>All You Need to Know About Franklin Resources</h3>
<p>Franklin Resources provides investment services for individual and institutional investors. At the end of June 2025, Franklin had $1.606 trillion in managed assets, composed primarily of equity (41%), fixed-income (28%), multi-asset/balanced (11%) funds, alternatives (16%) and money market funds (4%). Distribution tends to be weighted between retail investors (55% of AUM) and institutional accounts (42%), with high-net-worth clients accounting for the remainder. Franklin is one of the more global of the US-based asset managers we cover, with 30% of its assets under management invested in global/international strategies and just as much sourced from clients domiciled outside the United States.</p>
<h3>Unraveling the Financial Story of Franklin Resources</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Franklin Resources's revenue growth over 3 months faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately <strong>-1.92%</strong>. This indicates a decrease in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Franklin Resources's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>6.49%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Franklin Resources's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>1.11%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Franklin Resources's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.43%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Franklin Resources's debt-to-equity ratio is below the industry average at <strong>1.07</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/BEN/earnings"><strong>To track all earnings releases for Franklin Resources visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look Ahead: Franklin Resources's Earnings Forecast

<p>T. Rowe Price Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>) is gearing up to announce its quarterly earnings on Friday, 2025-08-01. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that T. Rowe Price Gr will report an <strong>earnings per share</strong> (EPS) of $2.10.</p>
<p>Investors in T. Rowe Price Gr are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.10, leading to a 0.0% drop in the share price the following trading session.</p>
<p>Here's a look at T. Rowe Price Gr's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.13</td>
<td>2.20</td>
<td>2.33</td>
<td>2.27</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.23</td>
<td>2.12</td>
<td>2.57</td>
<td>2.26</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>1.0%</td>
<td>2.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753970541_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of T. Rowe Price Gr were trading at $103.9 as of July 30. Over the last 52-week period, shares are down 2.77%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Analyst Views on T. Rowe Price Gr</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on T. Rowe Price Gr.</p>
<p>A total of 6 analyst ratings have been received for T. Rowe Price Gr, with the consensus rating being Neutral. The average one-year price target stands at $97.67, suggesting a potential 6.0% downside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Franklin Resources, Blue Owl Capital and SEI Investments, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Franklin Resources, with an average 1-year price target of $22.25, suggesting a potential 78.59% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Blue Owl Capital, with an average 1-year price target of $22.5, suggesting a potential 78.34% downside.</li>
<li>Analysts currently favor an Outperform trajectory for SEI Investments, with an average 1-year price target of $98.67, suggesting a potential 5.03% downside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Franklin Resources, Blue Owl Capital and SEI Investments, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>T. Rowe Price Group</td>
<td>Neutral</td>
<td>0.78%</td>
<td>$922M</td>
<td>4.61%</td>
</tr>
<tr>
<td>Franklin Resources</td>
<td>Neutral</td>
<td>-1.92%</td>
<td>$1.67B</td>
<td>1.11%</td>
</tr>
<tr>
<td>Blue Owl Capital</td>
<td>Outperform</td>
<td>33.14%</td>
<td>$357.55M</td>
<td>0.33%</td>
</tr>
<tr>
<td>SEI Investments</td>
<td>Outperform</td>
<td>7.83%</td>
<td>$301.13M</td>
<td>9.88%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>T. Rowe Price Gr ranks in the middle for consensus rating. It ranks at the bottom for revenue growth. It ranks at the top for gross profit. It ranks in the middle for return on equity.</p>
<h3>All You Need to Know About T. Rowe Price Gr</h3>
<p>T. Rowe Price provides asset management services for individual and institutional investors. It offers a broad range of no-load US and international stock, hybrid, bond, and money market funds. At the end of June 2025, the firm had $1.667 trillion in managed assets, composed of equity (50%), balanced (35%), fixed-income and money market (12%), and alternative (3%) offerings. Approximately two thirds of managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a US-based asset manager, deriving less than 10% of its AUM from overseas.</p>
<h3>T. Rowe Price Gr's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, T. Rowe Price Gr showcased positive performance, achieving a revenue growth rate of <strong>0.78%</strong> as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> T. Rowe Price Gr's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>27.1%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.61%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> T. Rowe Price Gr's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>3.48%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.05</strong>, T. Rowe Price Gr adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/TROW/earnings"><strong>To track all earnings releases for T. Rowe Price Gr visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


TROW

A Look at T. Rowe Price Gr's Upcoming Earnings Report

<p>Imperial Oil (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IMO#AMEX">IMO</a>) is gearing up to announce its quarterly earnings on Friday, 2025-08-01. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Imperial Oil will report an <strong>earnings per share</strong> (EPS) of $1.22.</p>
<p>Anticipation surrounds Imperial Oil's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company missed EPS by $0.09, leading to a 0.0% drop in the share price the following trading session.</p>
<p>Here's a look at Imperial Oil's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.84</td>
<td>2.18</td>
<td>1.50</td>
<td>1.42</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.75</td>
<td>1.69</td>
<td>1.71</td>
<td>1.54</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-7.000000000000001%</td>
<td>-5.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753970530_0.png" alt="eps graph" /></p>
<h3>Market Performance of Imperial Oil's Stock</h3>
<p>Shares of Imperial Oil were trading at $84.3 as of July 30. Over the last 52-week period, shares are up 23.03%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/IMO/earnings"><strong>To track all earnings releases for Imperial Oil visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Peek at Imperial Oil's Future Earnings

<p>Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) is preparing to release its quarterly earnings on Friday, 2025-08-01. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Colgate-Palmolive to report an <strong>earnings per share</strong> (EPS) of $0.89.</p>
<p>Investors in Colgate-Palmolive are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS beat by $0.05 in the last quarter, leading to a 0.0% drop in the share price on the following day.</p>
<p>Here's a look at Colgate-Palmolive's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.86</td>
<td>0.89</td>
<td>0.88</td>
<td>0.87</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.91</td>
<td>0.91</td>
<td>0.91</td>
<td>0.91</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-5.0%</td>
<td>-4.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753970523_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Colgate-Palmolive were trading at $85.8 as of July 30. Over the last 52-week period, shares are down 17.42%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Views on Colgate-Palmolive</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Colgate-Palmolive.</p>
<p>The consensus rating for Colgate-Palmolive is Buy, derived from 3 analyst ratings. An average one-year price target of $97.33 implies a potential 13.44% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Kimberly-Clark, Church &amp; Dwight Co and Reynolds Consumer Prods, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Kimberly-Clark, with an average 1-year price target of $135.5, suggesting a potential 57.93% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Church &amp; Dwight Co, with an average 1-year price target of $102.0, suggesting a potential 18.88% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Reynolds Consumer Prods, with an average 1-year price target of $23.0, suggesting a potential 73.19% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>Within the peer analysis summary, vital metrics for Kimberly-Clark, Church &amp; Dwight Co and Reynolds Consumer Prods are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colgate-Palmolive</td>
<td>Buy</td>
<td>-3.04%</td>
<td>$2.99B</td>
<td>240.00%</td>
</tr>
<tr>
<td>Kimberly-Clark</td>
<td>Neutral</td>
<td>-6.00%</td>
<td>$1.73B</td>
<td>58.42%</td>
</tr>
<tr>
<td>Church &amp; Dwight Co</td>
<td>Neutral</td>
<td>-2.41%</td>
<td>$659.60M</td>
<td>4.94%</td>
</tr>
<tr>
<td>Reynolds Consumer Prods</td>
<td>Neutral</td>
<td>-1.80%</td>
<td>$189M</td>
<td>1.45%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Colgate-Palmolive ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.</p>
<h3>Unveiling the Story Behind Colgate-Palmolive</h3>
<p>Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for north of 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which sells a majority of its products through veterinarians and specialty pet retailers.</p>
<h3>Colgate-Palmolive: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Colgate-Palmolive faced challenges, resulting in a decline of approximately <strong>-3.04%</strong> in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>14.05%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Colgate-Palmolive's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>240.0%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>4.22%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Colgate-Palmolive's debt-to-equity ratio surpasses industry norms, standing at <strong>22.78</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<p><a href="https://www.benzinga.com/quote/CL/earnings"><strong>To track all earnings releases for Colgate-Palmolive visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look Ahead: Colgate-Palmolive's Earnings Forecast

<p>Piper Sandler  analyst David Amsellem   maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Overweight and raises the price target from $154 to $175.</p>


News

Price Target

Analyst Ratings

NBIX

Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $175

<p>Financial giants have made a conspicuous bullish move on ServiceNow. Our analysis of options history for ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) revealed 14 unusual trades.</p>
<p>Delving into the details, we found 42% of traders were bullish, while 35% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $157,179, and 11 were calls, valued at $1,014,730.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $860.0 to $1040.0 for ServiceNow during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of ServiceNow stands at 159.33, with a total volume reaching 454.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in ServiceNow, situated within the strike price corridor from $860.0 to $1040.0, throughout the last 30 days.</p>
<h3>ServiceNow Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753970517_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$232.0</td>
<td>$219.2</td>
<td>$225.33</td>
<td>$900.00</td>
<td>$225.3K</td>
<td align="right">101</td>
<td align="right">0</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$199.0</td>
<td>$187.2</td>
<td>$193.13</td>
<td>$960.00</td>
<td>$193.1K</td>
<td align="right">31</td>
<td align="right">0</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/21/25</td>
<td>$73.0</td>
<td>$66.2</td>
<td>$69.6</td>
<td>$980.00</td>
<td>$139.2K</td>
<td align="right">49</td>
<td align="right">0</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$128.8</td>
<td>$121.3</td>
<td>$121.3</td>
<td>$900.00</td>
<td>$121.3K</td>
<td align="right">11</td>
<td align="right">0</td>
</tr>
<tr>
<td>NOW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/01/25</td>
<td>$6.8</td>
<td>$5.3</td>
<td>$5.65</td>
<td>$955.00</td>
<td>$84.1K</td>
<td align="right">333</td>
<td align="right">269</td>
</tr>
</tbody>
</table>
</p>
<h3>About ServiceNow</h3>
<p>ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.</p>
<p>Following our analysis of the options activities associated with ServiceNow, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of ServiceNow</h3>
<ul>
<li>With a volume of 178,991, the price of NOW is down -1.83% at $959.61. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 83 days.</li>
</ul>
<h3>Expert Opinions on ServiceNow</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $1158.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from B of A Securities persists with their Buy rating on ServiceNow, maintaining a target price of $1200.<br />
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Buy rating on ServiceNow with a target price of $1150.<br />
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Buy rating on ServiceNow with a target price of $1100.<br />
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for ServiceNow, targeting a price of $1234.<br />
&#x2A; An analyst from B of A Securities persists with their Buy rating on ServiceNow, maintaining a target price of $1110. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest ServiceNow options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Options

Markets

This Is What Whales Are Betting On ServiceNow

<p>Deep-pocketed investors have adopted a bullish approach towards Oklo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in OKLO usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 17 extraordinary options activities for Oklo. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 52% leaning bullish and 35% bearish. Among these notable options, 5 are puts, totaling $1,361,225, and 12 are calls, amounting to $1,374,448.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $30.0 and $100.0 for Oklo, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of Oklo stands at 4616.6, with a total volume reaching 3,342.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Oklo, situated within the strike price corridor from $30.0 to $100.0, throughout the last 30 days.</p>
<h3>Oklo 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753970512_0_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>OKLO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$12.45</td>
<td>$12.1</td>
<td>$12.3</td>
<td>$65.00</td>
<td>$615.0K</td>
<td>4.9K</td>
<td>500</td>
</tr>
<tr>
<td>OKLO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$12.25</td>
<td>$12.0</td>
<td>$12.15</td>
<td>$65.00</td>
<td>$607.5K</td>
<td>4.9K</td>
<td>1.5K</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$13.0</td>
<td>$12.4</td>
<td>$13.0</td>
<td>$100.00</td>
<td>$325.0K</td>
<td>5.7K</td>
<td>2</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$13.2</td>
<td>$12.95</td>
<td>$13.0</td>
<td>$100.00</td>
<td>$260.0K</td>
<td>5.7K</td>
<td>302</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$17.5</td>
<td>$17.15</td>
<td>$17.5</td>
<td>$80.00</td>
<td>$187.2K</td>
<td>1.3K</td>
<td>110</td>
</tr>
</tbody>
</table>
</p>
<h3>About Oklo</h3>
<p>Oklo Inc is developing advanced fission power plants to provide clean, reliable, and affordable energy at scale. It is pursuing two complementary tracks to address this demand: providing reliable, commercial-scale energy to customers; and selling used nuclear fuel recycling services to the U.S. market. The Company plans to commercialize its liquid metal fast reactor technology with the Aurora powerhouse product line. The first commercial Aurora powerhouse is designed to produce up to 15 megawatts of electricity (MWe) on both recycled nuclear fuel and fresh fuel.</p>
<p>In light of the recent options history for Oklo, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Oklo Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,916,281, the price of OKLO is up by 0.25%, reaching $75.82.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 11 days from now.</li>
</ul>
<h3>Expert Opinions on Oklo</h3>
<p>2 market experts have recently issued ratings for this stock, with a consensus target price of $70.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $73.<br />
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Neutral rating on Oklo with a target price of $68. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Oklo, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


OKLO

Behind the Scenes of Oklo's Latest Options Trends

<p><strong>Exxon Mobil</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) is set to give its latest quarterly earnings report on Friday, 2025-08-01. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Exxon Mobil will report an <strong>earnings per share</strong> (EPS) of $1.53. </p>
<p>Investors in Exxon Mobil are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings History Snapshot</h3>
<p>Last quarter the company beat EPS by $0.06, which was followed by a 0.0% drop in the share price the next day.</p>
<p>Here's a look at Exxon Mobil's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.70</td>
<td>1.55</td>
<td>1.88</td>
<td>2.01</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.76</td>
<td>1.67</td>
<td>1.92</td>
<td>2.14</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>-3.0%</td>
<td>-2.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753970512_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Exxon Mobil were trading at $111.9 as of July 30. Over the last 52-week period, shares are down 4.39%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analysts' Perspectives on Exxon Mobil</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Exxon Mobil.</p>
<p>A total of 8 analyst ratings have been received for Exxon Mobil, with the consensus rating being Outperform. The average one-year price target stands at $124.75, suggesting a potential 11.48% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Chevron, Shell and TotalEnergies, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Chevron, with an average 1-year price target of $167.3, suggesting a potential 49.51% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Shell, with an average 1-year price target of $81.2, suggesting a potential 27.44% downside.</li>
<li>Analysts currently favor an Neutral trajectory for TotalEnergies, with an average 1-year price target of $64.95, suggesting a potential 41.96% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>In the peer analysis summary, key metrics for Chevron, Shell and TotalEnergies are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exxon Mobil</td>
<td>Outperform</td>
<td>0.80%</td>
<td>$18.48B</td>
<td>2.93%</td>
</tr>
<tr>
<td>Chevron</td>
<td>Outperform</td>
<td>-1.03%</td>
<td>$13.37B</td>
<td>2.32%</td>
</tr>
<tr>
<td>Shell</td>
<td>Outperform</td>
<td>-4.48%</td>
<td>$12.71B</td>
<td>2.68%</td>
</tr>
<tr>
<td>TotalEnergies</td>
<td>Neutral</td>
<td>-9.16%</td>
<td>$12.26B</td>
<td>2.29%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Exxon Mobil ranks highest in revenue growth among its peers. It also leads in gross profit margin. However, it has the lowest return on equity compared to its peers.</p>
<h3>Unveiling the Story Behind Exxon Mobil</h3>
<p>ExxonMobil is an integrated oil and gas company that explores for, produces, and refines oil worldwide. In 2023, it produced 2.4 million barrels of liquids and 7.7 billion cubic feet of natural gas per day. At the end of 2023, reserves were 16.9 billion barrels of oil equivalent, 66% of which were liquids. The company is one of the world's largest refiners, with a total global refining capacity of 4.5 million barrels of oil per day, and is one of the world's largest manufacturers of commodity and specialty chemicals.</p>
<h3>Exxon Mobil's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Exxon Mobil showcased positive performance, achieving a revenue growth rate of <strong>0.8%</strong> as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Energy sector.</p>
<p><strong>Net Margin:</strong> Exxon Mobil's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>9.52%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Exxon Mobil's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.93%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.7%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Exxon Mobil's debt-to-equity ratio is below the industry average at <strong>0.14</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/XOM/earnings"><strong>To track all earnings releases for Exxon Mobil visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Examining the Future: Exxon Mobil's Earnings Outlook

General

ABBV

During Conf Call, AbbVie Exec Reportedly Says Under One Big Beautiful Bill Act Drugs With Multiple Orphan Designations Exempt From Ira Negotiations, A Benefit To Cancer Therapy Venclexta

<p>Financial giants have made a conspicuous bullish move on Meta Platforms. Our analysis of options history for Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) revealed 393 unusual trades.</p>
<p>Delving into the details, we found 43% of traders were bullish, while 29% showed bearish tendencies. Out of all the trades we spotted, 23 were puts, with a value of $1,483,254, and 370 were calls, valued at $37,922,919.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $400.0 to $1000.0 for Meta Platforms over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Meta Platforms's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Meta Platforms's substantial trades, within a strike price spectrum from $400.0 to $1000.0 over the preceding 30 days.</p>
<h3>Meta Platforms Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753970507_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>META</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$21.65</td>
<td>$21.4</td>
<td>$21.74</td>
<td>$780.00</td>
<td>$293.2K</td>
<td>2.3K</td>
<td>1.3K</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/01/25</td>
<td>$4.2</td>
<td>$4.0</td>
<td>$4.05</td>
<td>$790.00</td>
<td>$270.7K</td>
<td>5.1K</td>
<td>13.2K</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/01/25</td>
<td>$11.75</td>
<td>$11.7</td>
<td>$11.7</td>
<td>$780.00</td>
<td>$210.7K</td>
<td>8.1K</td>
<td>9.4K</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$65.5</td>
<td>$64.8</td>
<td>$65.5</td>
<td>$720.00</td>
<td>$170.3K</td>
<td>4.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/01/25</td>
<td>$62.55</td>
<td>$61.9</td>
<td>$62.24</td>
<td>$720.00</td>
<td>$124.4K</td>
<td>5.6K</td>
<td>2.9K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Meta Platforms</h3>
<p>Meta is the largest social media company in the world, boasting close to 4 billion monthly active users worldwide. The firm's "Family of Apps," its core business, consists of Facebook, Instagram, Messenger, and WhatsApp. End users can leverage these applications for a variety of different purposes, from keeping in touch with friends to following celebrities and running digital businesses for free. Meta packages customer data, gleaned from its application ecosystem and sells ads to digital advertisers. While the firm has been investing heavily in its Reality Labs business, it remains a very small part of Meta's overall sales.</p>
<h3>Meta Platforms's Current Market Status</h3>
<ul>
<li>With a volume of 10,996,834, the price of META is up 12.68% at $783.38. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 90 days.</li>
</ul>
<h3>Expert Opinions on Meta Platforms</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $816.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Keybanc has decided to maintain their Overweight rating on Meta Platforms, which currently sits at a price target of $800.<br />
&#x2A; An analyst from Keybanc has decided to maintain their Overweight rating on Meta Platforms, which currently sits at a price target of $905.<br />
&#x2A; Consistent in their evaluation, an analyst from Bernstein keeps a Outperform rating on Meta Platforms with a target price of $775.<br />
&#x2A; An analyst from TD Cowen persists with their Buy rating on Meta Platforms, maintaining a target price of $800.<br />
&#x2A; Consistent in their evaluation, an analyst from Benchmark keeps a Buy rating on Meta Platforms with a target price of $800. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Meta Platforms, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Meta Platforms's Options: A Look at What the Big Money is Thinking

<p>Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) will release its quarterly earnings report on Friday, 2025-08-01. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Regeneron Pharmaceuticals to report an <strong>earnings per share</strong> (EPS) of $7.55.</p>
<p>The announcement from Regeneron Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Historical Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $0.60, leading to a 5.25% increase in the share price on the subsequent day.</p>
<p>Here's a look at Regeneron Pharmaceuticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>8.82</td>
<td>11.19</td>
<td>11.69</td>
<td>10.53</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>8.22</td>
<td>12.07</td>
<td>12.46</td>
<td>11.56</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>5.0%</td>
<td>3.0%</td>
<td>1.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753970502_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Regeneron Pharmaceuticals were trading at $554.58 as of July 30. Over the last 52-week period, shares are down 48.62%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analysts' Take on Regeneron Pharmaceuticals</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Regeneron Pharmaceuticals.</p>
<p>Analysts have given Regeneron Pharmaceuticals a total of 12 ratings, with the consensus rating being Outperform. The average one-year price target is $727.83, indicating a potential 31.24% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of  and Alnylam Pharmaceuticals, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Alnylam Pharmaceuticals, with an average 1-year price target of $360.18, suggesting a potential 35.05% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>The peer analysis summary presents essential metrics for  and Alnylam Pharmaceuticals, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regeneron Pharmaceuticals</td>
<td>Outperform</td>
<td>-3.70%</td>
<td>$2.56B</td>
<td>2.75%</td>
</tr>
<tr>
<td>Alnylam Pharmaceuticals</td>
<td>Buy</td>
<td>20.20%</td>
<td>$523.15M</td>
<td>-62.98%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Regeneron Pharmaceuticals ranks higher in Revenue Growth compared to its peers. It also has a higher Gross Profit margin. However, its Return on Equity is lower than the average of its peers.</p>
<h3>All You Need to Know About Regeneron Pharmaceuticals</h3>
<p>Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).</p>
<h3>Unraveling the Financial Story of Regeneron Pharmaceuticals</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Regeneron Pharmaceuticals's financials over 3 months reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately <strong>-3.7%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Regeneron Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>26.7%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>2.75%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Regeneron Pharmaceuticals's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>2.15%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.09</strong>.</p>
<p><a href="https://www.benzinga.com/quote/REGN/earnings"><strong>To track all earnings releases for Regeneron Pharmaceuticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


REGN

Exploring Regeneron Pharmaceuticals's Earnings Expectations

<p>UBS  analyst Timothy Arcuri   maintains Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) with a Neutral and lowers the price target from $95 to $90.</p>


ENTG

UBS Maintains Neutral on Entegris, Lowers Price Target to $90

<p>Ratings for Fortive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) were provided by 14 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $70.29, a high estimate of $87.00, and a low estimate of $50.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 12.45%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753970501_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A clear picture of Fortive's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$55.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Brett Linzey</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Joseph Giordano</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$50.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Brian Gesuale</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$55.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$75.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$79.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$78.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Richard Eastman</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Fortive. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Fortive compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Fortive's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>To gain a panoramic view of Fortive's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FTV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Fortive analyst ratings.</strong></a></p>
<h2>Delving into Fortive's Background</h2>
<p>Fortive is a diversified industrial technology firm with a broad portfolio of mission-critical products and services that include field solutions, product realization, health, and sensing technologies. The company serves a wide range of end markets, including manufacturing, utilities, medical, and electronics. Fortive generated roughly $6.2 billion in revenue in 2024.</p>
<h3>Fortive's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Fortive's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately <strong>-3.3%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> Fortive's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>11.66%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Fortive's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>1.68%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Fortive's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>1.01%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Fortive's debt-to-equity ratio is below the industry average. With a ratio of <b>0.38</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Fortive Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)

<p>Fuchs Petrolub (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUPBY#OTC">FUPBY</a>) reported quarterly earnings of $0.14 per share. This is a 12.5 percent decrease over earnings of $0.16 per share from the same period last year.  The company reported $997.746 million in sales this quarter. This is a 4.48 percent increase over sales of $954.953 million the same period last year.</p>


FUPBY

Fuchs Petrolub Q2 Earnings Per ADS $0.14 Down From $0.16 YoY, Sales $997.746M Up From $954.953M YoY

<p>9 analysts have shared their evaluations of Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Merit Medical Systems and provided 12-month price targets. The average target is $107.78, accompanied by a high estimate of $112.00 and a low estimate of $103.00. Marking an increase of 1.36%, the current average surpasses the previous average price target of $106.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753970490_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive Merit Medical Systems is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$103.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$108.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$108.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$108.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$108.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$108.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Merit Medical Systems. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Merit Medical Systems compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Merit Medical Systems's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into Merit Medical Systems's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MMSI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Merit Medical Systems analyst ratings.</strong></a></p>
<h2>Get to Know Merit Medical Systems Better</h2>
<p>Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.</p>
<h3>A Deep Dive into Merit Medical Systems's Financials</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Merit Medical Systems's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>9.84%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Merit Medical Systems's net margin is impressive, surpassing industry averages. With a net margin of <strong>8.48%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Merit Medical Systems's ROE excels beyond industry benchmarks, reaching <strong>2.15%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Merit Medical Systems's ROA excels beyond industry benchmarks, reaching <strong>1.23%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.57</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MMSI

9 Analysts Have This To Say About Merit Medical Systems

<p>Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) will release its quarterly earnings report on Friday, 2025-08-01. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Chevron to report an <strong>earnings per share</strong> (EPS) of $1.70.</p>
<p>The market awaits Chevron's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings Track Record</h3>
<p>In the previous earnings release, the company missed EPS by $0.00, leading to a 0.0% drop in the share price the following trading session.</p>
<p>Here's a look at Chevron's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.18</td>
<td>2.11</td>
<td>2.43</td>
<td>2.93</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.18</td>
<td>2.06</td>
<td>2.51</td>
<td>2.55</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>-5.0%</td>
<td>3.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753970483_0.png" alt="eps graph" /></p>
<h3>Performance of Chevron Shares</h3>
<p>Shares of Chevron were trading at $153.56 as of July 30. Over the last 52-week period, shares are up 3.09%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Perspectives on Chevron</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Chevron.</p>
<p>Analysts have given Chevron a total of 10 ratings, with the consensus rating being Outperform. The average one-year price target is $167.3, indicating a potential 8.95% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Shell, Exxon Mobil and TotalEnergies, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Shell, with an average 1-year price target of $81.2, suggesting a potential 47.12% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Exxon Mobil, with an average 1-year price target of $124.75, suggesting a potential 18.76% downside.</li>
<li>Analysts currently favor an Neutral trajectory for TotalEnergies, with an average 1-year price target of $64.95, suggesting a potential 57.7% downside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
<p>Within the peer analysis summary, vital metrics for Shell, Exxon Mobil and TotalEnergies are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chevron</td>
<td>Outperform</td>
<td>-1.03%</td>
<td>$13.37B</td>
<td>2.32%</td>
</tr>
<tr>
<td>Shell</td>
<td>Outperform</td>
<td>-4.48%</td>
<td>$12.71B</td>
<td>2.68%</td>
</tr>
<tr>
<td>Exxon Mobil</td>
<td>Outperform</td>
<td>0.80%</td>
<td>$18.48B</td>
<td>2.93%</td>
</tr>
<tr>
<td>TotalEnergies</td>
<td>Neutral</td>
<td>-9.16%</td>
<td>$12.26B</td>
<td>2.29%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Chevron ranks highest in revenue growth among its peers. It also leads in gross profit margin. However, it has the lowest return on equity compared to its peers.</p>
<h3>About Chevron</h3>
<p>Chevron is an integrated energy company with exploration, production, and refining operations worldwide. It is the second-largest oil company in the United States with production of 3.0 million of barrels of oil equivalent a day, including 7.7 million cubic feet a day of natural gas and 1.7 million of barrels of liquids a day. Production activities take place in North America, South America, Europe, Africa, Asia, and Australia. Its refineries are in the US and Asia for total refining capacity of 1.8 million barrels of oil a day. Proven reserves at year-end 2024 stood at 9.8 billion barrels of oil equivalent, including 5.1 billion barrels of liquids and 28.4 trillion cubic feet of natural gas.</p>
<h3>Chevron: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Chevron faced challenges, resulting in a decline of approximately <strong>-1.03%</strong> in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> Chevron's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>7.59%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Chevron's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>2.32%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Chevron's ROA excels beyond industry benchmarks, reaching <strong>1.36%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Chevron's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.2</strong>.</p>
<p><a href="https://www.benzinga.com/quote/CVX/earnings"><strong>To track all earnings releases for Chevron visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look at Chevron's Upcoming Earnings Report

<p>Guggenheim  analyst Gregory Francfort   maintains Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) with a Buy and raises the price target from $325 to $410.</p>


WING

Guggenheim Maintains Buy on Wingstop, Raises Price Target to $410

<p>Ratings for Element Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESI#NYSE">ESI</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $27.67, along with a high estimate of $30.00 and a low estimate of $24.00. This upward trend is apparent, with the current average reflecting a 8.51% increase from the previous average price target of $25.50.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753970478_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Element Solutions among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$27.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$29.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$29.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Element Solutions. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Element Solutions compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Element Solutions's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Element Solutions's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ESI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Element Solutions analyst ratings.</strong></a></p>
<h2>About Element Solutions</h2>
<p>Element Solutions Inc is a specialty chemicals company whose businesses supply a broad range of solutions that enhance the performance of products people use every day. The company's reportable segments are Electronics and Industrial &amp; Specialty. The Electronics segment, which generates maximum revenue, researches, formulates, and sells specialty chemicals and process technologies for all types of electronics hardware, from complex printed circuit board designs to semiconductor packaging. This segment's wet chemicals for metallization, surface treatments, and solderable finishes form the physical circuitry pathways, and its assembly materials, such as solder, pastes, fluxes, and adhesives, join those pathways together.</p>
<h3>Element Solutions's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Element Solutions's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>3.25%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Materials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>16.51%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Element Solutions's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>4.0%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Element Solutions's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.03%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Element Solutions's debt-to-equity ratio is below the industry average. With a ratio of <b>0.64</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What 6 Analyst Ratings Have To Say About Element Solutions

<p>W.W. Grainger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) is gearing up to announce its quarterly earnings on Friday, 2025-08-01. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that W.W. Grainger will report an <strong>earnings per share</strong> (EPS) of $10.04.</p>
<p>Investors in W.W. Grainger are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Historical Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.37, which was followed by a 1.38% increase in the share price the next day.</p>
<p>Here's a look at W.W. Grainger's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>9.49</td>
<td>9.74</td>
<td>9.97</td>
<td>9.61</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>9.86</td>
<td>9.71</td>
<td>9.87</td>
<td>9.76</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-6.0%</td>
<td>-0.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1753970472_0.png" alt="eps graph" /></p>
<h3>Tracking W.W. Grainger's Stock Performance</h3>
<p>Shares of W.W. Grainger were trading at $1042.67 as of July 30. Over the last 52-week period, shares are up 9.65%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Insights Shared by Analysts on W.W. Grainger</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on W.W. Grainger.</p>
<p>A total of 3 analyst ratings have been received for W.W. Grainger, with the consensus rating being Neutral. The average one-year price target stands at $1143.0, suggesting a potential 9.62% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Fastenal, Ferguson Enterprises and United Rentals, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Fastenal, with an average 1-year price target of $42.0, suggesting a potential 95.97% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Ferguson Enterprises, with an average 1-year price target of $228.36, suggesting a potential 78.1% downside.</li>
<li>Analysts currently favor an Outperform trajectory for United Rentals, with an average 1-year price target of $870.62, suggesting a potential 16.5% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>The peer analysis summary presents essential metrics for Fastenal, Ferguson Enterprises and United Rentals, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>W.W. Grainger</td>
<td>Neutral</td>
<td>1.68%</td>
<td>$1.71B</td>
<td>14.01%</td>
</tr>
<tr>
<td>Fastenal</td>
<td>Neutral</td>
<td>8.56%</td>
<td>$942.80M</td>
<td>8.81%</td>
</tr>
<tr>
<td>Ferguson Enterprises</td>
<td>Outperform</td>
<td>4.28%</td>
<td>$2.36B</td>
<td>7.44%</td>
</tr>
<tr>
<td>United Rentals</td>
<td>Outperform</td>
<td>4.51%</td>
<td>$1.53B</td>
<td>6.98%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>W.W. Grainger ranks first in gross profit among its peers. It is in the middle for consensus rating and revenue growth. The company ranks second for return on equity.</p>
<h3>Get to Know W.W. Grainger Better</h3>
<p>Founded in 1927, W.W. Grainger originally distributed various motors via a mail-order catalogue. Over the course of the 20th century, the firm expanded into new industrial product categories and launched its first digital catalogue in 1995. Today, the company organizes itself into two segments focused on different customer bases. Its larger segment, high-touch solutions, offers a vast array of maintenance, repair, and operations, or MRO, supplies and bespoke inventory management services to larger businesses. Its smaller segment, endless assortment, operates two online platforms, Zoro and MonotaRO, that offer comprehensive catalogues of MRO supplies to smaller businesses. Grainger has operations throughout the world but primarily generates sales within the US.</p>
<h3>Understanding the Numbers: W.W. Grainger's Finances</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining W.W. Grainger's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>1.68%</strong> as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> W.W. Grainger's net margin is impressive, surpassing industry averages. With a net margin of <strong>11.12%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> W.W. Grainger's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>14.01%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>5.48%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.77</strong>.</p>
<p><a href="https://www.benzinga.com/quote/GWW/earnings"><strong>To track all earnings releases for W.W. Grainger visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Preview Of W.W. Grainger's Earnings

Press Releases

LivaNova to Present at the Barclays Global Healthcare Conference

LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

LivaNova to Announce First-Quarter 2025 Results

LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy

LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

LivaNova to Present at the Jefferies Global Healthcare Conference

LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression

LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

Comments

LivaNova

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL